Introduction
Antidepressant drugs have been in extensive use for over 20 years. Initially 2 groups of compounds, the monoamine oxidase inhibitors (MAOI) and tricyclic compounds based on the imipramine configuration were widely used. In the early 1960's after a few years of wide use, interest in the MAOI group fell following the recognition of a serious adverse effect. Blackwell (1963) described the occurrence of hypertensive crisis with occasional fatalities when these compounds were taken with certain foodstuffs. It is of interest, however, that in recent years there has been some resurgence of interest in these compounds and the suggestion that their dangers may have been exaggerated (Tyrer, 1979) or might be ameliorated by combination with tricyclics (Pare et al., 1982) . Interest in the tricyclic group however has continued unabated and over the years at least 20 antidepressants based on the original imipramine configuration have been produced. There is now a widespread and extensive accumulated experience of these compounds and although they remain the most widely prescribed antidepressant, it is now clear that they have a number of serious disadvantages. The most important of these are cardiotoxicity, potential fatality in overdose, marked peripheral anticholinergic activity and reduction in seizure threshold (Blackwell, 1981a) . As these disadvantages exist to some extent with all the tricyclics produced so far, there have, not surprisingly, been active attempts to produce different and safer antidepressant compounds.
Over the last few years a number of different compounds have come into use as antidepressants and these constitute the 'second generation' antidepressant drugs. Included among these are; viloxazine and zimelidine, both bicyclic compounds; nomifensine, a tetrahydro-isoquinoline derivative; maprotiline, a bridged tricyclic compound and the tetracyclic compound mianserin. All (Itil, Polvan and Hsu, 1972 (Murphy, Donald and Molla, 1976; Branconnier, Cole and Ghazvinian, 1981) .
Comparison with tricyclic antidepressants. A large number of double-blind trials of varying methodological sophistication comparing mianserin with standard tricyclic antidepressants have been reported (Pinder and Fink, 1982) . These include comparison with amitriptyline (Wheatley, 1975; Coppen et al., 1976; Montgomery et al., 1978; Murphy and Bridgeman, 1978; Daly, Brown and Morgan, 1979; Kretschmar, 1980 ) with imipramine (Murphy, 1975; Pichot, Dreyfus and Pull, 1978) and with clomipramine (Blaha, Pinder and Stulemeijer, 1980; De Buck, 1980) . The detection of differences in efficacy between 2 compounds both having active properties, in small groups of patients is difficult. It is therefore perhaps not surprising that almost all of these comparisons between mianserin and tricyclics have concluded that they are indistinguishable in efficacy and onset of action. An important factor however emanating from these trials is the apparent paucity of side effects emerging on treatment with mianserin. Daily dosage in these studies ranged from 20-30 mg for mianserin and 75-300 mg for the tricyclics.
Side effects
Mianserin has sedative properties and drowsiness is the most frequently reported side effect. However, this often diminishes within the first week. The clinical trials suggest that peripheral anticholinergic effects are rare and occur to a less extent than with tricyclics. These observations from therapeutic trials are supported by experimental double-blind studies in depressed patients (Ghose, Coppen and Turner, 1976; Wilson, Petrie and Ban, 1980) and in normal volunteers (Kopera, 1980) .
A further important feature emerging from clinical trials with mianserin is an apparent lack of cardiovascular problems such as increased heart rate and hypotension. Burgess et al. (1979) , in an analysis of the cardiovascular effects of mianserin and other antidepressants, reported that mianserin lacked the cardiotoxic and negative inotropic effects of the tricyclic antidepressants. Experimental studies in intact animal hearts, whole animals and in healthy subjects further demonstrate a lack of cardiotoxicity for mianserin (Harper and Hughes, 1977; Kopera et al., 1980) . Adams et aL (1983) , in this journal, provide clinical details on a further 4 of these cases, one of whom died. In the last few months, 2 additional cases of mianserin-induced agranulocytosis have been reported (Page, 1982; Achar, 1982) .
White cell depression usually occurs early, typically at between 4 and 6 weeks after the start of treatment. It typically presents with oral ulceration and a sore throat. The neutrophil count in most of these cases was severely reduced to 0 2 x 109/litre or less, but, typically, complete recovery occurred once the drug was withdrawn.
This association of mianserin with a small number of cases of blood dyscrasia should be viewed against the background that all psychotropic drugs are reported as being associated with some form of blood dyscrasia. Nevertheless, it dictates that all patients receiving mianserin should be carefully observed particularly during the first few weeks of treatment. In the event of the patient developing symptoms of infection such as fever, stomatitis or sore throat the drug should be stopped immediately and full haematological investigation started. It might be prudent, where possible, for patients to have regular blood counts with a particular focus at between 4 and 6 weeks. It should be emphasized however that the key to the early detection of side effects is regular careful and direct clinical observation of patients.
Conclusions
There is evidence to indicate that mianserin has antidepressant activity. It is generally well tolerated and appears to have a low propensity for interaction with many of the commonly used drugs. Due 
